1921
Control and Elimination of Plasmodium vivax Malaria: The Evidence Base
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

There is inadequate understanding of the biology, pathology, transmission, and control of , the geographically most widespread cause of human malaria. During the last decades, study of this species was neglected, in part due to the erroneous belief that it is intrinsically benign. In addition, many technical challenges in culturing the parasite also hampered understanding its fundamental biology and molecular and cellular responses to chemotherapeutics. Research on vivax malaria needs to be substantially expanded over the next decade to accelerate its elimination and eradication. This article summarizes key knowledge gaps identified by researchers, national malaria control programs, and other stakeholders assembled by the World Health Organization to develop strategies for controlling and eliminating vivax malaria. The priorities presented in this article emerged in these technical discussions, and were adopted by expert consensus of the authors. All involved understood the priority placed upon pragmatism in this research agenda, that is, focus upon tools delivering better prevention, diagnosis, treatment, and surveillance of .

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0180
2016-12-28
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/6_Suppl/62.html?itemId=/content/journals/10.4269/ajtmh.16-0180&mimeType=html&fmt=ahah

References

  1. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN, , 2012. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol 80: 271300.[Crossref]
  2. World Health Organization, 2014. Severe malaria. Trop Med Int Health 19 (Suppl 1): 7131.
  3. World Health Organization, 2014. World Malaria Report 2014. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/malaria/publications/world_malaria_report_2014/en/.
  4. Childs DZ, Cattadori IM, Suwonkerd W, Prajakwong S, Boots M, , 2006. Spatiotemporal patterns of malaria incidence in northern Thailand. Trans R Soc Trop Med Hyg 100: 623631.[Crossref]
  5. Coura JR, Suarez-Mutis M, Ladeia-Andrade S, , 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection—a review. Mem Inst Oswaldo Cruz 101: 229237.
  6. Rosenberg R, , 2007. Plasmodium vivax in Africa: hidden in plain sight? Trends Parasitol 23: 193196.[Crossref]
  7. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI, , 2012. The global public health significance of Plasmodium vivax . Adv Parasitol 80: 1111.[Crossref]
  8. Durnez L, Mao S, Denis L, Roelants P, Sochantha T, Coosemans M, , 2013. Outdoor malaria transmission in forested villages of Cambodia. Malar J 12: 329.[Crossref]
  9. World Health Organization, 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: World Health Organization.
  10. Golenda CF, Li J, Rosenberg R, , 1997. Continuous in vitro propagation of the malaria parasite Plasmodium vivax . Proc Natl Acad Sci USA 94: 67866791.[Crossref]
  11. Galinski MR, Meyer EV, Barnwell JW, , 2013. Plasmodium vivax: modern strategies to study a persistent parasite's life cycle. Adv Parasitol 81: 126.[Crossref]
  12. Noulin F, Borlon C, Van Den Abbeele J, D'Alessandro U, Erhart A, , 2013. 1912–2012: a century of research on Plasmodium vivax in vitro culture. Trends Parasitol 29: 286294.[Crossref]
  13. Borlon C, Russell B, Sriprawat K, Suwanarusk R, Erhart A, Renia L, Nosten F, D'Alessandro U, , 2012. Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used for invasion and short term culture. Int J Parasitol 42: 155160.[Crossref]
  14. Chotivanich K, Silamut K, Udomsangpetch R, Stepniewska KA, Pukrittayakamee S, Looareesuwan S, White NJ, , 2001. Ex-vivo short-term culture and developmental assessment of Plasmodium vivax . Trans R Soc Trop Med Hyg 95: 677680.[Crossref]
  15. Udomsangpetch R, Somsri S, Panichakul T, Chotivanich K, Sirichaisinthop J, Yang Z, Cui L, Sattabongkot J, , 2007. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol Int 56: 6569.[Crossref]
  16. Dembele L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, Le Grand R, Dereuddre-Bosquet N, van Gemert GJ, Sauerwein R, Vaillant JC, Hannoun L, Fuchter MJ, Diagana TT, Malmquist NA, Scherf A, Snounou G, Mazier D, , 2014. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat Med 20: 307312.[Crossref]
  17. Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, Rezakhani N, Lakshmanan V, Singh N, Kaushansky A, Camargo N, Baldwin M, Lindner SE, Adams JH, Sattabongkot J, Kappe SH, , 2015. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe 17: 526535.[Crossref]
  18. Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, , 1976. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg 70: 474481.[Crossref]
  19. Costa FT, Lopes SC, Ferrer M, Leite JA, Martin-Jaular L, Bernabeu M, Nogueira PA, Mourao MP, Fernandez-Becerra C, Lacerda MV, del Portillo H, , 2011. On cytoadhesion of Plasmodium vivax: raison d'etre? Mem Inst Oswaldo Cruz 106 (Suppl 1): 7984.[Crossref]
  20. Baird JK, , 2013. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 26: 3657.[Crossref]
  21. Barber BE, William T, Grigg MJ, Parameswaran U, Piera KA, Price RN, Yeo TW, Anstey NM, , 2015. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog 11: e1004558.[Crossref]
  22. White NJ, Imwong M, , 2012. Relapse. Adv Parasitol 80: 113150.[Crossref]
  23. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I, , 2009. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 199: 10741080.[Crossref]
  24. de Araujo FC, de Rezende AM, Fontes CJ, Carvalho LH, Alves de Brito CF, , 2012. Multiple-clone activation of hypnozoites is the leading cause of relapse in Plasmodium vivax infection. PLoS One 7: e49871.[Crossref]
  25. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ, , 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927933.[Crossref]
  26. Bright AT, Manary MJ, Tewhey R, Arango EM, Wang T, Schork NJ, Yanow SK, Winzeler EA, , 2014. A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Negl Trop Dis 8: e2882.[Crossref]
  27. Lin JT, Hathaway NJ, Saunders DL, Lon C, Balasubramanian S, Kharabora O, Gosi P, Sriwichai S, Kartchner L, Chuor CM, Satharath P, Lanteri C, Bailey JA, Juliano JJ, , 2015. Using amplicon deep sequencing to detect genetic signatures of Plasmodium vivax relapse. J Infect Dis 212: 9991008.[Crossref]
  28. Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, Hofmann NE, Kinboro B, Waltmann A, Brewster J, Lorry L, Tarongka N, Samol L, Silkey M, Bassat Q, Siba PM, Schofield L, Felger I, Mueller I, , 2015. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med 12: e1001891.[Crossref]
  29. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, , 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57: 11281135.[Crossref]
  30. McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, Elliott S, Whiley D, Sloots T, Winzeler EA, Trenholme KR, , 2013. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis 208: 16881694.[Crossref]
  31. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, , 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555566.[Crossref]
  32. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I, , 2012. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 206: 17711780.[Crossref]
  33. Douglas NM, Simpson JA, Phyo AP, Siswantoro H, Hasugian AR, Kenangalem E, Poespoprodjo JR, Singhasivanon P, Anstey NM, White NJ, Tjitra E, Nosten F, Price RN, , 2013. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax . J Infect Dis 208: 801812.[Crossref]
  34. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, Anstey NM, Price RN, , 2013. Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study. PLoS Med 10: e1001575.[Crossref]
  35. Siqueira AM, Lacerda MV, Magalhaes BM, Mourao MP, Melo GC, Alexandre MA, Alecrim MG, Kochar D, Kochar S, Kochar A, Nayak K, Del Portillo H, Guinovart C, Alonso P, Bassat Q, , 2015. Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India. BMC Med 13: 57.[Crossref]
  36. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singhasivanon P, White NJ, Nosten FH, , 2012. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12: 388396.[Crossref]
  37. Anstey N, Russell B, Yeo T, Price R, , 2009. The pathophysiology of vivax malaria. Trends Parasitol 25: 220226.[Crossref]
  38. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q, , 2012. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis 55: e67e74.[Crossref]
  39. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, Mamoni R, Leite JA, Rodrigues MM, Soares IS, Oliveira TR, Wunderlich G, Lacerda MV, del Portillo HA, Araujo MO, Russell B, Suwanarusk R, Snounou G, Renia L, Costa FT, , 2010. On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J Infect Dis 202: 638647.[Crossref]
  40. Lacerda MV, Mourao MP, Alexandre MA, Siqueira AM, Magalhaes BM, Martinez-Espinosa FE, Filho FS, Brasil P, Ventura AM, Tada MS, Couto VS, Silva AR, Silva RS, Alecrim MG, , 2012. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J 11: 12.[Crossref]
  41. Culleton RL, Ferreira PE, , 2012. Duffy phenotype and Plasmodium vivax infections in humans and apes, Africa. Emerg Infect Dis 18: 17041705.[Crossref]
  42. Culleton RL, Mita T, Ndounga M, Unger H, Cravo PV, Paganotti GM, Takahashi N, Kaneko A, Eto H, Tinto H, Karema C, D'Alessandro U, do Rosario V, Kobayakawa T, Ntoumi F, Carter R, Tanabe K, , 2008. Failure to detect Plasmodium vivax in west and central Africa by PCR species typing. Malar J 7: 174.[Crossref]
  43. Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, Takeo S, Tsuboi T, Yadava A, Carter R, Tanabe K, , 2009. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, west central Africa. J Infect Dis 200: 14651469.[Crossref]
  44. Ryan JR, Stoute JA, Joseph A, Dunton RF, Ramadhan M, Joseph K, Boaz O, Shirley L, Wirtz RA, Barnwell JW, Ronald R, , 2006. Evidence for transmission of Plasmodium vivax among a Duffy antigen negative population in western Kenya. Am J Trop Med Hyg 75: 575581.
  45. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, Bradley J, Grignard L, Lanke KH, Wanzira H, Mpimbaza A, Nsobya S, White NJ, Webb EL, Staedke SG, Drakeley C, , 2014. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 14: 130139.[Crossref]
  46. Ketema T, Bacha K, , 2013. Plasmodium vivax associated severe malaria complications among children in some malaria endemic areas of Ethiopia. BMC Public Health 13: 637.[Crossref]
  47. Abdallah T, Abdeen M, Ahmed I, Hamdan H, Magzoub M, Adam I, , 2013. Severe Plasmodium falciparum and Plasmodium vivax malaria among adults at Kassala Hospital, eastern Sudan. Malar J 12: 148.[Crossref]
  48. Mahgoub H, Gasim G, Musa I, Adam I, , 2012. Severe Plasmodium vivax malaria among Sudanese children at New Halfa Hospital. Eastern Sudan Parasit Vec 5: 154.[Crossref]
  49. Muhlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjorup I, Behrens RH, Clerinx J, Bjorkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJ, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Gomez i Prat J, Lehmann V, Bouchaud O, da Cunha S, Atouguia J, Boecken G, , 2004. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 3: 5.[Crossref]
  50. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A, , 2009. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in southeast Asians. Science 326: 15461549.[Crossref]
  51. Leslie T, Briceño M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, Whitty CJM, Rowland M, , 2010. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med 7: e1000283.[Crossref]
  52. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, , 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 13811382.[Crossref]
  53. Durnez L, Coosemans M, Manguin S, , 2013. Residual transmission of malaria: an old issue for new approaches. , ed. Anopheles Mosquitoes - New Insights into Malaria Vectors. Intech, 671704. Available from: http://www.intechopen.com/books/anopheles-mosquitoes-new-insights-into-malaria-vectors/residual-transmission-of-malaria-an-old-issue-for-new-approaches.
  54. Bockarie MJ, Service MW, Toure YT, Traore S, Barnish G, Greenwood BM, , 1993. The ecology and behaviour of the forest form of Anopheles gambiae s.s. Parassitologia 35 (Suppl): 58.
  55. Hemingway J, Beaty BJ, Rowland M, Scott TW, Sharp BL, , 2006. The Innovative Vector Control Consortium: improved control of mosquito-borne diseases. Trends Parasitol 22: 308312.[Crossref]
  56. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD, Palacios R, Chen-Mok M, Corradin G, Arevalo-Herrera M, , 2005. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73: 39.
  57. Richie TL, Billingsley PF, Sim BK, Epstein JE, Lyke KE, Mordmuller B, Alonso P, Duffy PE, Doumbo OK, Sauerwein RW, Tanner M, Abdulla S, Kremsner PG, Seder RA, Hoffman SL, , 2015. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33: 74527461.[Crossref]
  58. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 13591365.[Crossref]
  59. Mauduit M, Gruner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Renia L, , 2009. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS One 4: e7717.[Crossref]
  60. Yadava A, Nurmukhambetova S, Pichugin AV, Lumsden JM, , 2012. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria. J Infect Dis 205: 14561463.[Crossref]
  61. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S, Gujja S, Goldberg JM, Young S, Zeng Q, Chapman SB, Dash AP, Anvikar AR, Sutton PL, Birren BW, Escalante AA, Barnwell JW, Carlton JM, , 2012. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum . Nat Genet 44: 10461050.[Crossref]
  62. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, , 2013. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133201.[Crossref]
  63. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Menard D, Bancone G, Winasti-Satyahraha A, Vestergaard LS, Green J, Domingo G, Yeung S, Price R, , 2013. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 12: 112.[Crossref]
  64. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW, , 2015. Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res 165: 677688.[Crossref]
  65. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, , 2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14: 982991.[Crossref]
  66. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, , 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405416.[Crossref]
  67. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, , 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.[Crossref]
  68. World Health Organization, 2015. Guidelines for the Treatment of Malaria. Geneva, Switzerland: World Health Organization.
  69. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L, , 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 10491058.[Crossref]
  70. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q, , 2010. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J 9: 254.[Crossref]
  71. malERA Consultative Group on Diagnoses and Diagnostics, 2011. A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med 8: e1000396.[Crossref]
  72. Abdul-Ghani R, Al-Mekhlafi AM, Karanis P, , 2012. Loop-mediated isothermal amplification (LAMP) for malarial parasites of humans: would it come to clinical reality as a point-of-care test? Acta Trop 122: 233240.[Crossref]
  73. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC, , 2014. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. eLife 3: e04692.[Crossref]
  74. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, Cromer D, Davenport MP, , 2015. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis 9: e0003595.[Crossref]
  75. Bassat Q, , 2014. The importance of being vivax. J Trop Pediatr 60: 335337.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0180
Loading
  • Received : 07 Mar 2016
  • Accepted : 11 May 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error